Core Insights - NeuroSense Therapeutics is participating in the 2024 International Symposium on ALS/MND, showcasing its commitment to ALS research and treatment development [1][5] - The company will present findings from its Phase 2b PARADIGM trial of PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS) [2][3] Company Overview - NeuroSense Therapeutics is a late-clinical stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, including ALS [1][11] - The company aims to address significant unmet medical needs in neurodegenerative diseases through innovative therapies and biomarker research [11] Clinical Trial Details - The PARADIGM trial is a Phase 2b clinical trial involving 68 participants across Canada, Italy, and Israel, designed to evaluate the efficacy of PrimeC in ALS [8] - The trial demonstrated a 29% efficacy difference in favor of PrimeC compared to placebo in the intent-to-treat population, with a statistically significant 37.4% slowing of disease progression observed in the ALS Functional Rating Scale-Revised (ALSFRS-R) [9] Treatment Insights - PrimeC is an extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, targeting multiple mechanisms of ALS [10] - The drug has shown promising results in previous trials, including significant changes in ALS-related biological markers and a reduction in functional and respiratory deterioration [10] Symposium Participation - Key presentations at the symposium will include insights from leading experts in ALS research, such as Prof. Merit Cudkowicz and Dr. Cristian Lunetta, focusing on clinical outcomes and biomarker analysis from the PARADIGM trial [3][4] - The presence of NeuroSense's management team at the symposium highlights the company's leadership role in advancing ALS research [4]
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND